Cargando…

The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9

Imbalance of macrophage polarization plays an indispensable role in acute lung injury (ALI), which is considered as a promising target. Matrix metalloproteinase-9 (MMP-9) is expressed in the macrophage, and has a pivotal role in secreting inflammatory cytokines. We reported that saquinavir (SQV), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Yao, Yu, Zhuang, Chen, Zhixia, Zhang, Renlingzi, Ding, Xibing, Yang, Xiaohu, Niu, Xiaoyin, Li, Mengzhu, Zhang, Lingling, Billiar, Timothy R., Pitt, Bruce R., Li, Quan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798387/ https://www.ncbi.nlm.nih.gov/pubmed/33431821 http://dx.doi.org/10.1038/s41419-020-03320-0

Ejemplares similares

Saquinavir Ameliorates Liver Warm Ischemia-Reperfusion-Induced Lung Injury via HMGB-1- and P38/JNK-Mediated TLR-4-Dependent Signaling Pathways
por: Yu, Zhuang, et al.
Publicado: (2017)

WISP1 mediates lung injury following hepatic ischemia reperfusion dependent on TLR4 in mice
por: Tong, Yao, et al.
Publicado: (2018)

WISP1-αvβ3 integrin signaling positively regulates TLR-triggered inflammation response in sepsis induced lung injury
por: Chen, Zhixia, et al.
Publicado: (2016)

Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis
por: Liu, Haixia, et al.
Publicado: (2022)

Mechanical ventilation enhances extrapulmonary sepsis-induced lung injury: role of WISP1–αvβ5 integrin pathway in TLR4-mediated inflammation and injury
por: Ding, Xibing, et al.
Publicado: (2018)

Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment
por: Dallas, Shannon, et al.
Publicado: (2013)

Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug
por: Jayaswal, Amit, et al.
Publicado: (2014)

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines
por: Bandiera, Elisabetta, et al.
Publicado: (2016)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011)

Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir
por: Venkatachalam, Sankaran, et al.
Publicado: (2023)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
por: Stephan, C, et al.
Publicado: (2010)

Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA
por: Bello, Martiniano, et al.
Publicado: (2020)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury
por: Ding, Xibing, et al.
Publicado: (2017)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2010)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Identification of autophagy-related genes and immune cell infiltration characteristics in sepsis via bioinformatic analysis
por: Di, Chong, et al.
Publicado: (2023)

Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery
por: Bojic, Suzana, et al.
Publicado: (2018)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4(+) immune cells
por: Yang, Sidi, et al.
Publicado: (2013)

Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats
por: Li, Jiapeng, et al.
Publicado: (2016)

Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation
por: Rana, Nilottam, et al.
Publicado: (2022)

Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study
por: Wang, Miaomiao, et al.
Publicado: (2014)

Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis
por: Jones, Tiffanie K., et al.
Publicado: (2022)

Impact of pro-domain stability of matrix metalloproteinase-8 on the outcome of sepsis
por: McLaughlin, J, et al.
Publicado: (2011)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells
por: Pereira, Mariana, et al.
Publicado: (2022)

Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
por: Hoffmann, Ursula, et al.
Publicado: (2009)

Genomic variations within matrix metalloproteinase-9 and severe sepsis
por: Chen, Q, et al.
Publicado: (2009)

Genetic Variants of Matrix Metalloproteinase and Sepsis: The Need Speed Study
por: Fiotti, Nicola, et al.
Publicado: (2022)

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2009)

Targeting adaptor protein SLP76 of RAGE as a therapeutic approach for lethal sepsis
por: Yan, Zhengzheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_auk408ssha13q97cv8ll2c8kev